DRG Epidemiology's coverage of clostridium difficile infection comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report both the incidence and prevalence of clostridium difficile infection for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology's clostridium difficile infection forecast will answer the following questions:
Of all people diagnosed with clostridium difficile infection, how many in each country across the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of clostridium difficile infection over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following clostridium difficile infection patient populations:
Diagnosed Events-Hospital by Frequency
Clostridium Difficile Infection Diagnosed Events – Hospital
Clostridium Difficile Infection Diagnosed Events-Nursing Home
Comorbidities-Initial Events subpopulation(s)
Diagnosed Events-Nursing Home by Frequency
Diagnosed Events-Severity subpopulation(s)
Comorbidities-Recurrent Events subpopulation(s)
Initial Events-Severe Complicated subpopulation(s)
Initial Events-Severity subpopulation(s)
Recurrent Events-Severe Complicated subpopulation(s)
… and more (details available on request).
Note: coverage may vary by country and region.